{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T17:37:55Z","timestamp":1792949875842,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["G20AI174733"],"award-info":[{"award-number":["G20AI174733"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P01AI097092"],"award-info":[{"award-number":["P01AI097092"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93021C00014"],"award-info":[{"award-number":["75N93021C00014"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00051"],"award-info":[{"award-number":["75N93019C00051"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00051"],"award-info":[{"award-number":["75N93019C00051"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21AI176069"],"award-info":[{"award-number":["R21AI176069"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21AI151229"],"award-info":[{"award-number":["R21AI151229"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI141226"],"award-info":[{"award-number":["R01AI141226"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-024-00952-7","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T07:02:52Z","timestamp":1726729372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Sequential immunization with chimeric hemagglutinin \u0394NS1 attenuated influenza vaccines induces broad humoral and cellular immunity"],"prefix":"10.1038","volume":"9","author":[{"given":"Raveen","family":"Rathnasinghe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3287-3987","authenticated-orcid":false,"given":"Lauren A.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Pearl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Jangra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Aspelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaura","family":"Hoag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soner","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5464-7086","authenticated-orcid":false,"given":"Ignacio","family":"Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2435-5047","authenticated-orcid":false,"given":"Weina","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-8036","authenticated-orcid":false,"given":"Madhumathi","family":"Loganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas Alexander","family":"Crossland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans P.","family":"Gertje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4791-374X","authenticated-orcid":false,"given":"Anna Elise","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3748-4227","authenticated-orcid":false,"given":"Sadaf","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4008-503X","authenticated-orcid":false,"given":"Randy A.","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0337-5823","authenticated-orcid":false,"given":"Peter","family":"Palese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-776X","authenticated-orcid":false,"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3156-3132","authenticated-orcid":false,"given":"Michael","family":"Schotsaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Muster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6551-1827","authenticated-orcid":false,"given":"Adolfo","family":"Garc\u00eda-Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"key":"952_CR1","doi-asserted-by":"publisher","first-page":"A6","DOI":"10.1016\/j.vaccine.2020.09.048","volume":"39","author":"AE Macias","year":"2021","unstructured":"Macias, A. E. et al. The disease burden of influenza beyond respiratory illness. Vaccine 39, A6\u2013A14 (2021).","journal-title":"Vaccine"},{"key":"952_CR2","doi-asserted-by":"crossref","unstructured":"Grohskopf, L. A. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2019\u201320 influenza season. MMWR Recomm. Rep. 68 (2019).","DOI":"10.15585\/mmwr.rr6803a1"},{"key":"952_CR3","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1016\/j.jaip.2021.08.003","volume":"9","author":"RB Kennedy","year":"2021","unstructured":"Kennedy, R. B., Ovsyannikova, I. G. & Poland, G. A. Update on Influenza Vaccines: needs and progress. J. Allergy Clin. Immunol. Pract. 9, 3599\u20133603 (2021).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"952_CR4","doi-asserted-by":"crossref","unstructured":"Gonzalez, K. J. & Strauch, E. M. Decreased vaccine protection of egg-based influenza vaccine in the elderly and nonhemagglutinin-focused immunity. J. Clin. Invest. 131 (2021).","DOI":"10.1172\/JCI151732"},{"key":"952_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","volume":"19","author":"F Krammer","year":"2019","unstructured":"Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383\u2013397 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"952_CR6","doi-asserted-by":"publisher","first-page":"D49","DOI":"10.1016\/j.vaccine.2008.07.039","volume":"26","author":"NM Bouvier","year":"2008","unstructured":"Bouvier, N. M. & Palese, P. The biology of influenza viruses. Vaccine 26, D49\u2013D53 (2008).","journal-title":"Vaccine"},{"key":"952_CR7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1056\/NEJMp038238","volume":"350","author":"J Treanor","year":"2004","unstructured":"Treanor, J. Influenza vaccine\u2014outmaneuvering antigenic shift and drift. N. Engl. J. Med. 350, 218\u2013220 (2004).","journal-title":"N. Engl. J. Med."},{"key":"952_CR8","doi-asserted-by":"publisher","first-page":"eaau5485","DOI":"10.1126\/scitranslmed.aau5485","volume":"11","author":"JK Taubenberger","year":"2019","unstructured":"Taubenberger, J. K., Kash, J. C. & Morens, D. M. The 1918 influenza pandemic: 100 years of questions answered and unanswered. Sci. Transl. Med. 11, eaau5485 (2019).","journal-title":"Sci. Transl. Med."},{"key":"952_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41591-018-0340-z","volume":"25","author":"S Yamayoshi","year":"2019","unstructured":"Yamayoshi, S. & Kawaoka, Y. Current and future influenza vaccines. Nat. Med. 25, 212\u2013220 (2019).","journal-title":"Nat. Med."},{"key":"952_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.0300-9475.2004.01382.x","volume":"59","author":"R Cox","year":"2004","unstructured":"Cox, R., Brokstad, K. & Ogra, P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59, 1\u201315 (2004).","journal-title":"Scand. J. Immunol."},{"key":"952_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/vaccines3020373","volume":"3","author":"S Sridhar","year":"2015","unstructured":"Sridhar, S., Brokstad, K. A. & Cox, R. J. Influenza vaccination strategies: comparing inactivated and live attenuated influenza vaccines. Vaccines 3, 373\u2013389 (2015).","journal-title":"Vaccines"},{"key":"952_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/infdis\/jiz321","volume":"221","author":"S Lartey","year":"2020","unstructured":"Lartey, S. et al. Live-attenuated influenza vaccine induces tonsillar follicular T helper cell responses that correlate with antibody induction. J. Infect. Dis. 221, 21\u201332 (2020).","journal-title":"J. Infect. Dis."},{"key":"952_CR13","doi-asserted-by":"publisher","first-page":"e00114","DOI":"10.1128\/JVI.00114-18","volume":"92","author":"A Aljurayyan","year":"2018","unstructured":"Aljurayyan, A. et al. Activation and induction of antigen-specific T follicular helper cells (TFH) play a critical role in LAIV-induced human mucosal anti-influenza antibody response. J. Virol. 92, e00114\u2013e00118 (2018).","journal-title":"J. Virol."},{"key":"952_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1128\/jcm.24.1.157-160.1986","volume":"24","author":"M Clements","year":"1986","unstructured":"Clements, M., Betts, R., Tierney, E. & Murphy, B. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J. Clin. Microbiol. 24, 157\u2013160 (1986).","journal-title":"J. Clin. Microbiol."},{"key":"952_CR15","doi-asserted-by":"publisher","first-page":"103608","DOI":"10.3389\/fimmu.2014.00331","volume":"5","author":"DL Turner","year":"2014","unstructured":"Turner, D. L. & Farber, D. L. Mucosal resident memory CD4 T cells in protection and immunopathology. Front. Immunol. 5, 103608 (2014).","journal-title":"Front. Immunol."},{"key":"952_CR16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/icb.2009.16","volume":"87","author":"LE Brown","year":"2009","unstructured":"Brown, L. E. & Kelso, A. Prospects for an influenza vaccine that induces cross\u2010protective cytotoxic T lymphocytes. Immunol. Cell Biol. 87, 300\u2013308 (2009).","journal-title":"Immunol. Cell Biol."},{"key":"952_CR17","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/nm.3350","volume":"19","author":"S Sridhar","year":"2013","unstructured":"Sridhar, S. et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19, 1305\u20131312 (2013).","journal-title":"Nat. Med."},{"key":"952_CR18","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/nrmicro2613","volume":"9","author":"RA Medina","year":"2011","unstructured":"Medina, R. A. & Garc\u00eda-Sastre, A. Influenza A viruses: new research developments. Nat. Rev. Microbiol. 9, 590\u2013603 (2011).","journal-title":"Nat. Rev. Microbiol."},{"key":"952_CR19","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.vaccine.2017.01.018","volume":"35","author":"A Hampson","year":"2017","unstructured":"Hampson, A. et al. Improving the selection and development of influenza vaccine viruses\u2013Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18\u201320 November 2015. Vaccine 35, 1104\u20131109 (2017).","journal-title":"Vaccine"},{"key":"952_CR20","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/irv.12383","volume":"10","author":"JP Weir","year":"2016","unstructured":"Weir, J. P. & Gruber, M. F. An overview of the regulation of influenza vaccines in the United States. Influenza Other Respir. Viruses 10, 354\u2013360 (2016).","journal-title":"Influenza Other Respir. Viruses"},{"key":"952_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/infdis\/jiy103","volume":"218","author":"EJ Erbelding","year":"2018","unstructured":"Erbelding, E. J. et al. A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases. J. Infect. Dis. 218, 347\u2013354 (2018).","journal-title":"J. Infect. Dis."},{"key":"952_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev-med-120611-145115","volume":"64","author":"N Pica","year":"2013","unstructured":"Pica, N. & Palese, P. Toward a universal influenza virus vaccine: prospects and challenges. Annu. Rev. Med. 64, 189\u2013202 (2013).","journal-title":"Annu. Rev. Med."},{"key":"952_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1146\/annurev-med-120617-041310","volume":"71","author":"R Nachbagauer","year":"2020","unstructured":"Nachbagauer, R. & Palese, P. Is a universal influenza virus vaccine possible? Annu. Rev. Med. 71, 315\u2013327 (2020).","journal-title":"Annu. Rev. Med."},{"key":"952_CR24","doi-asserted-by":"crossref","unstructured":"Krammer, F., Garc\u00eda-Sastre, A. & Palese, P. Is it possible to develop a \u201cuniversal\u201d influenza virus vaccine? Toward a universal influenza virus vaccine: potential target antigens and critical aspects for vaccine development. Cold Spring Harb. Perspect. Biol. a028845 (2017).","DOI":"10.1101\/cshperspect.a028845"},{"key":"952_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/npjvaccines.2016.15","volume":"1","author":"R Nachbagauer","year":"2016","unstructured":"Nachbagauer, R. et al. A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice. Npj Vaccines 1, 1\u201310 (2016).","journal-title":"Npj Vaccines"},{"key":"952_CR26","doi-asserted-by":"crossref","unstructured":"Krammer, F., Natalie, P., Hai, R., Margine, I. & Palese, P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87, 6542\u20136550 (2013).","DOI":"10.1128\/JVI.00641-13"},{"key":"952_CR27","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1128\/JVI.03183-13","volume":"88","author":"F Krammer","year":"2014","unstructured":"Krammer, F. et al. H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J. Virol. 88, 2340\u20132343 (2014).","journal-title":"J. Virol."},{"key":"952_CR28","doi-asserted-by":"publisher","first-page":"e00286","DOI":"10.1128\/JVI.00286-17","volume":"91","author":"ME Ermler","year":"2017","unstructured":"Ermler, M. E. et al. Chimeric hemagglutinin constructs induce broad protection against influenza b virus challenge in the mouse model. J. Virol. 91, e00286\u201317 (2017).","journal-title":"J. Virol."},{"key":"952_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/S1473-3099(19)30393-7","volume":"20","author":"DI Bernstein","year":"2020","unstructured":"Bernstein, D. I. et al. Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Lancet Infect. Dis. 20, 80\u201391 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"952_CR30","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3389\/fimmu.2019.00756","volume":"10","author":"W-C Liu","year":"2019","unstructured":"Liu, W.-C. et al. Sequential immunization with live-attenuated chimeric hemagglutinin-based vaccines confers heterosubtypic immunity against influenza A viruses in a preclinical Ferret model. Front. Immunol. 10, 756 (2019).","journal-title":"Front. Immunol."},{"key":"952_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/vaccines9010040","volume":"9","author":"W-C Liu","year":"2021","unstructured":"Liu, W.-C. et al. Chimeric hemagglutinin-based live-attenuated vaccines confer durable protective immunity against influenza A viruses in a preclinical Ferret model. Vaccines 9, 40 (2021).","journal-title":"Vaccines"},{"key":"952_CR32","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1016\/j.vaccine.2019.05.013","volume":"37","author":"C Nicolodi","year":"2019","unstructured":"Nicolodi, C. et al. Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1. Vaccine 37, 3722\u20133729 (2019).","journal-title":"Vaccine"},{"key":"952_CR33","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1086\/649428","volume":"201","author":"V Wacheck","year":"2010","unstructured":"Wacheck, V. et al. A novel type of influenza vaccine: safety and immunogenicity of replication\u2010deficient influenza virus created by deletion of the interferon antagonist NS1. J. Infect. Dis. 201, 354\u2013362 (2010).","journal-title":"J. Infect. Dis."},{"key":"952_CR34","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1006\/viro.1998.9508","volume":"252","author":"A Garc\u00eda-Sastre","year":"1998","unstructured":"Garc\u00eda-Sastre, A. et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252, 324\u2013330 (1998).","journal-title":"Virology"},{"key":"952_CR35","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1099\/0022-1317-73-12-3325","volume":"73","author":"E Hatada","year":"1992","unstructured":"Hatada, E. & Fukuda, R. Binding of influenza A virus NS1 protein to dsRNA in vitro. J. Gen. Virol. 73, 3325\u20133329 (1992).","journal-title":"J. Gen. Virol."},{"key":"952_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2015.01.007","volume":"12","author":"RM Krug","year":"2015","unstructured":"Krug, R. M. Functions of the influenza A virus NS1 protein in antiviral defense. Curr. Opin. Virol. 12, 1\u20136 (2015).","journal-title":"Curr. Opin. Virol."},{"key":"952_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2217\/fmb.09.108","volume":"5","author":"BG Hale","year":"2010","unstructured":"Hale, B. G., Albrecht, R. A. & Garc\u00eda-Sastre, A. Innate immune evasion strategies of influenza viruses. Future Microbiol 5, 23\u201341 (2010).","journal-title":"Future Microbiol"},{"key":"952_CR38","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1099\/vir.0.2008\/004606-0","volume":"89","author":"BG Hale","year":"2008","unstructured":"Hale, B. G., Randall, R. E., Ort\u00edn, J. & Jackson, D. The multifunctional NS1 protein of influenza A viruses. J. Gen. Virol. 89, 2359\u20132376 (2008).","journal-title":"J. Gen. Virol."},{"key":"952_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01780-8","volume":"11","author":"R Rathnasinghe","year":"2021","unstructured":"Rathnasinghe, R. et al. Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1. Sci. Rep. 11, 22164 (2021).","journal-title":"Sci. Rep."},{"key":"952_CR40","doi-asserted-by":"publisher","first-page":"6295","DOI":"10.1128\/JVI.02381-05","volume":"80","author":"A Fernandez-Sesma","year":"2006","unstructured":"Fernandez-Sesma, A. et al. Influenza Virus Evades Innate and Adaptive Immunity via the NS1 Protein. J. Virol. 80, 6295\u20136304 (2006).","journal-title":"J. Virol."},{"key":"952_CR41","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1016\/j.vaccine.2014.02.009","volume":"32","author":"A Morokutti","year":"2014","unstructured":"Morokutti, A., Muster, T. & Ferko, B. Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans. Vaccine 32, 1897\u20131900 (2014).","journal-title":"Vaccine"},{"key":"952_CR42","doi-asserted-by":"publisher","first-page":"e02332","DOI":"10.1128\/mBio.02332-17","volume":"9","author":"F Krammer","year":"2018","unstructured":"Krammer, F. et al. NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines? mBio 9, e02332\u201317 (2018).","journal-title":"mBio"},{"key":"952_CR43","doi-asserted-by":"crossref","unstructured":"Zens, K. D., Chen, J. K. & Farber, D. L. Vaccine-generated lung tissue\u2013resident memory T cells provide heterosubtypic protection to influenza infection. JCI Insight 1 (2016).","DOI":"10.1172\/jci.insight.85832"},{"key":"952_CR44","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.4049\/jimmunol.179.4.2115","volume":"179","author":"K Tewari","year":"2007","unstructured":"Tewari, K., Nakayama, Y. & Suresh, M. Role of direct effects of IFN-\u03b3 on T cells in the regulation of CD8 T cell homeostasis. J. Immunol. 179, 2115\u20132125 (2007).","journal-title":"J. Immunol."},{"key":"952_CR45","first-page":"375","volume":"67","author":"CD Mackenzie","year":"1989","unstructured":"Mackenzie, C. D., Taylor, P. M. & Askonas, B. A. Rapid recovery of lung histology correlates with clearance of influenza virus by specific CD8+ cytotoxic T cells. Immunology 67, 375\u2013381 (1989).","journal-title":"Immunology"},{"key":"952_CR46","doi-asserted-by":"crossref","unstructured":"Guo, H. H., Sweeney, R. T. & Regula, D., Leung, A. & Fatal, N. 2009 Influenza A (H1N1) infection, complicated by acute respiratory distress syndrome and pulmonary interstitial emphysema. RadioGraphics 30, 327\u2013333 (2010).","DOI":"10.1148\/rg.302095213"},{"key":"952_CR47","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1183\/09031936.00186214","volume":"45","author":"S Herold","year":"2015","unstructured":"Herold, S., Becker, C., Ridge, K. M. & Budinger, G. R. S. Influenza virus-induced lung injury: pathogenesis and implications for treatment. Eur. Respir. J. 45, 1463\u20131478 (2015).","journal-title":"Eur. Respir. J."},{"key":"952_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1056\/NEJMp1714916","volume":"378","author":"CI Paules","year":"2018","unstructured":"Paules, C. I., Sullivan, S. G., Subbarao, K. & Fauci, A. S. Chasing seasonal influenza\u2014the need for a universal influenza vaccine. N. Engl. J. Med. 378, 7\u20139 (2018).","journal-title":"N. Engl. J. Med."},{"key":"952_CR49","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1016\/j.vaccine.2012.04.109","volume":"30","author":"E Van Riet","year":"2012","unstructured":"Van Riet, E., Ainai, A., Suzuki, T. & Hasegawa, H. Mucosal IgA responses in influenza virus infections; thoughts for vaccine design. Vaccine 30, 5893\u20135900 (2012).","journal-title":"Vaccine"},{"key":"952_CR50","doi-asserted-by":"publisher","first-page":"226","DOI":"10.4049\/jimmunol.166.1.226","volume":"166","author":"BP Arulanandam","year":"2001","unstructured":"Arulanandam, B. P. et al. IgA immunodeficiency leads to inadequate Th cell priming and increased susceptibility to influenza virus infection. J. Immunol. 166, 226\u2013231 (2001).","journal-title":"J. Immunol."},{"key":"952_CR51","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.coviro.2013.07.007","volume":"3","author":"F Krammer","year":"2013","unstructured":"Krammer, F. & Palese, P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr. Opin. Virol. 3, 521\u2013530 (2013).","journal-title":"Curr. Opin. Virol."},{"key":"952_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28706-1","volume":"8","author":"E Kirkpatrick","year":"2018","unstructured":"Kirkpatrick, E., Qiu, X., Wilson, P. C., Bahl, J. & Krammer, F. The influenza virus hemagglutinin head evolves faster than the stalk domain. Sci. Rep. 8, 10432 (2018).","journal-title":"Sci. Rep."},{"key":"952_CR53","doi-asserted-by":"publisher","first-page":"e03617","DOI":"10.1128\/mBio.03617-20","volume":"12","author":"EK Roubidoux","year":"2021","unstructured":"Roubidoux, E. K. et al. Mutations in the hemagglutinin stalk domain do not permit escape from a protective, stalk-based vaccine-induced immune response in the mouse model. mBio 12, e03617\u2013e03620 (2021).","journal-title":"mBio"},{"key":"952_CR54","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4049\/immunohorizons.1900022","volume":"3","author":"A Choi","year":"2019","unstructured":"Choi, A. et al. Chimeric hemagglutinin-based influenza virus vaccines induce protective stalk-specific humoral immunity and cellular responses in mice. ImmunoHorizons 3, 133\u2013148 (2019).","journal-title":"ImmunoHorizons"},{"key":"952_CR55","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1073\/pnas.070525997","volume":"97","author":"J Talon","year":"2000","unstructured":"Talon, J. et al. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc. Natl Acad. Sci. 97, 4309\u20134314 (2000).","journal-title":"Proc. Natl Acad. Sci."},{"key":"952_CR56","doi-asserted-by":"crossref","unstructured":"Mallajosyula, V. V. A. et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc. Natl. Acad. Sci. 111 (2014).","DOI":"10.1073\/pnas.1402766111"},{"key":"952_CR57","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.antiviral.2013.03.021","volume":"98","author":"NS Laursen","year":"2013","unstructured":"Laursen, N. S. & Wilson, I. A. Broadly neutralizing antibodies against influenza viruses. Antivir. Res. 98, 476\u2013483 (2013).","journal-title":"Antivir. Res."},{"key":"952_CR58","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/j.vaccine.2020.01.008","volume":"38","author":"V Chromikova","year":"2020","unstructured":"Chromikova, V. et al. Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay. Vaccine 38, 1953\u20131961 (2020).","journal-title":"Vaccine"},{"key":"952_CR59","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/icb.2012.78","volume":"91","author":"E Grant","year":"2013","unstructured":"Grant, E. et al. Nucleoprotein of influenza A virus is a major target of immunodominant CD8 + T\u2010cell responses. Immunol. Cell Biol. 91, 184\u2013194 (2013).","journal-title":"Immunol. Cell Biol."},{"key":"952_CR60","doi-asserted-by":"publisher","first-page":"101397","DOI":"10.1016\/j.coviro.2024.101397","volume":"65","author":"S Lee","year":"2024","unstructured":"Lee, S., Yeung, K. K. & Watts, T. H. Tissue-resident memory T cells in protective immunity to influenza virus. Curr. Opin. Virol. 65, 101397 (2024).","journal-title":"Curr. Opin. Virol."},{"key":"952_CR61","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/21645515.2017.1377376","volume":"14","author":"KG-I Mohn","year":"2018","unstructured":"Mohn, K. G.-I., Smith, I., Sjursen, H. & Cox, R. J. Immune responses after live attenuated influenza vaccination. Hum. Vaccines Immunother. 14, 571\u2013578 (2018).","journal-title":"Hum. Vaccines Immunother."},{"key":"952_CR62","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1348-0421.2000.tb02516.x","volume":"44","author":"T Ito","year":"2000","unstructured":"Ito, T. Interspecies transmission and receptor recognition of influenza A viruses. Microbiol. Immunol. 44, 423\u2013430 (2000).","journal-title":"Microbiol. Immunol."},{"key":"952_CR63","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1743-422X-3-63","volume":"3","author":"M Matrosovich","year":"2006","unstructured":"Matrosovich, M., Matrosovich, T., Garten, W. & Klenk, H.-D. New low-viscosity overlay medium for viral plaque assays]. Virol. J. 3, 63 (2006).","journal-title":"Virol. J."},{"key":"952_CR64","doi-asserted-by":"publisher","first-page":"e0147723","DOI":"10.1371\/journal.pone.0147723","volume":"11","author":"M Breen","year":"2016","unstructured":"Breen, M., Nogales, A., Baker, S. F., Perez, D. R. & Mart\u00ednez-Sobrido, L. Replication-competent influenza A and B viruses expressing a fluorescent dynamic timer protein for in vitro and in vivo studies. PLoS ONE 11, e0147723 (2016).","journal-title":"PLoS ONE"},{"key":"952_CR65","doi-asserted-by":"crossref","unstructured":"Margine, I., Palese, P. & Krammer, F. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J. Vis. Exp. 81, 51112 (2013)","DOI":"10.3791\/51112-v"},{"key":"952_CR66","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1128\/jvi.70.6.4188-4192.1996","volume":"70","author":"S Pleschka","year":"1996","unstructured":"Pleschka, S. et al. A plasmid-based reverse genetics system for influenza A virus. J. Virol. 70, 4188\u20134192 (1996).","journal-title":"J. Virol."},{"key":"952_CR67","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.1222908","volume":"337","author":"C Dreyfus","year":"2012","unstructured":"Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343\u20131348 (2012).","journal-title":"Science"},{"key":"952_CR68","first-page":"16","volume":"28","author":"M Ramakrishnan","year":"2018","unstructured":"Ramakrishnan, M. & Muthuchelvan, D. Influence of reed-muench median dose calculation method in virology in the millennium. Antivir. Res. 28, 16\u201317 (2018).","journal-title":"Antivir. Res."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00952-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00952-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00952-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T07:05:26Z","timestamp":1726729526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00952-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["952"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-00952-7","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"20 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The A.G.-S. laboratory has received research support from GSK, Pfizer, Senhwa Biosciences, Kenall Manufacturing, Blade Therapeutics, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, Applied Biological Laboratories and Merck. A.G.-S. has consulting agreements for the following companies involving cash and\/or stock: Castlevax, Amovir, Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Pagoda, Accurius, Esperovax, Farmak, Applied Biological Laboratories, Pharmamar, CureLab Oncology, CureLab Veterinary, Synairgen, Paratus, Pfizer and Prosetta. A.G.-S. has been an invited speaker in meeting events organized by Seqirus, Janssen, Abbott and AstraZeneca. A.G.-S. and P.P. are inventors on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York. The M.S. laboratory has received unrelated funding support in sponsored research agreements from Phio Pharmaceuticals, 7Hills Pharma, ArgenX, and Moderna. The Icahn School of Medicine at Mount Sinai has filed patent applications regarding influenza virus vaccines on which F.K. is listed as inventor. The Krammer laboratory has received support for influenza virus research in the past from GSK and is currently receiving support from Dynavax. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics vaccines, which lists F.K. as co-inventor. Several of these patents have been licensed and F.K. has received royalty payments from commercial entities. F.K. has consulted from Merck, Pfizar, Seqirus, GSK and Curevac and is currently consulting for Gritstone, 3rd Rock Ventures and Avimex and he is co-founder and scientific advisory board member of Castlevax. The F.K. laboratory is also collaborating with Dynavax on influenza virus vaccine development and with VIR on influenza therapeutics. T.M. is inventor on patents and patent applications on vaccines and immunotherapies, owned by Vivaldi Biosciences and BlueSky Immunotherapies. T.M. owns stocks and options from BlueSky Immunotherapies, Nuvonis Technologies and Vivaldi Biosciences. A.A. is inventor on patents and patent applications on vaccines and immunotherapies, owned by Vivaldi Biosciences and BlueSky Immunotherapies. A.A. owns stock options from Vivaldi Biosciences. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}